Skip to main content

View Dr Young's bio on PubMed

Selected Publications

Journal Articles

Kang JH, Bluestone JA, Young A (2021). Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines. Trends Immunol, 42(4), 293-311.

Quandt Z, Coupe C, Anderson M, Uihlein A, Young A (2020). Breaking β Cell Tolerance After 100 Years of Life: Intratumoral Immunotherapy-Induced Diabetes Mellitus. J Endocr Soc, 4(10), bvaa114.

Quandt Z, Young A, Perdigoto AL, Herold KC, Anderson MS (2021). Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Annu Rev Med, 72, 313-330.

Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowery CT, Daud A, Bluestone JA (2020). Regulatory T cell control of systemic immunity and immunotherapy response in liver Sci Immunol, 5(52).

Young A, Quandt Z, Bluestone JA (2018). The Balancing Act between Cancer Immunity and Autoimmunity in Response to Cancer Immunol Res, 6(12), 1445-1452.

Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC (2018). Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Diabetes, 67(8), 1471-1480.

Wang D, Quiros J, Mahuron K, Pai CC, Ranzani V, Young A, Silveria S, Harwin T, Abnousian A, Pagani M, Rosenblum MD, Van Gool F, Fong L, Bluestone JA, DuPage M (2018). Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Cell Rep, 23(11), 3262-3274.

Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, Lin G, Coudert JD, Stannard KA, Zitvogel L, Degli-Esposti MA, Vivier E, Waddell N, Linden J, Huntington ND, Souza-Fonseca-Guimaraes F, Smyth MJ (2018). A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment. Cancer Res, 78(4), 1003-1016.

Vijayan D, Young A, Teng MWL, Smyth MJ (2017). Targeting immunosuppressive adenosine in Nat Rev Cancer, 17(12), 709-724.

Young A, Ngiow SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, Bald T, Barkauskas DS, Ahern E, Huntington ND, Schadendorf D, Long GV, Boyle GM, Hölzel M, Scolyer RA, Smyth MJ (2017). Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Cancer Res, 77(17), 4684-4696.

Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, Huang Q, Liu J, Takeda K, Teng MWL, Sachsenmeier K, Smyth MJ (2016). Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Cancer Cell, 30(3), 391-403.

Ngiow SF, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, Smyth MJ (2015). A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res, 75(18), 3800-11.

Souza-Fonseca-Guimaraes F, Young A, Mittal D, Martinet L, Bruedigam C, Takeda K, Andoniou CE, Degli-Esposti MA, Hill GR, Smyth MJ (2015). NK cells require IL-28R for optimal in vivo Proc Natl Acad Sci U S A, 112(18), E2376-84.

Young A, Mittal D, Stannard K, Yong M, Teng MW, Allard B, Stagg J, Smyth MJ (2014). Co-blockade of immune checkpoints and adenosine A2A receptor suppresses metastasis. Oncoimmunology, 3(10),

Young A, Berry R, Holloway AF, Blackburn NB, Dickinson JL, Skala M, Phillips JL, Brettingham-Moore KH (2014). RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization. BMC Cancer, 14, 808.

Young A, Mittal D, Stagg J, Smyth MJ (2014). Targeting cancer-derived adenosine: new therapeutic Cancer Discov, 4(8), 879-88.

Case Reports

Quandt Z, Coupe C, Anderson M, Uihlein A, Young A (2020). Breaking β Cell Tolerance After 100 Years of Life: Intratumoral Immunotherapy-Induced Diabetes Mellitus. J Endocr Soc, 4(10), bvaa114.


Souza-Fonseca-Guimaraes F, Young A, Smyth MJ (2015). IFN type III: in vivo NK cell response. Oncotarget, 6(24), 19960-1.